Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Multi-agent Low Dose Chemotherapy (Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, Irinotecan) Followed by Maintenance Olaparib and Pembrolizumab in Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Summary

The purpose of this phase II trial is to evaluate the safety and efficacy of maintenance olaparib and pembrolizumab following multi agent, low dose chemotherapy with gemcitabine, nab-paclitaxel, capecitabine, cisplatin, and irinotecan in patients with untreated metastatic adenocarcinoma.

General Information

NCT#: NCT04753879
Study ID: J2112
Trial Phase: Phase II

Trial Sponsor: Merck Sharp & Dohme Corp., Sidney Kimmel Comprehensive Cancer Center
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, Capecitabine, Irinotecan, Cisplatin, Olaparib, Pembrolizumab

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search